|ARYx Therapeutics, Inc.|
6300 Dumbarton Circle
United States - Map
ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with commercialized drugs in the United States. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The companys other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics was incorporated in 1997 and is based in Fremont, California.
|Dr. Paul Goddard Ph.D.,
Chairman and Chief Exec. Officer
|Mr. John Varian ,
Chief Operating Officer
|Mr. David Nagler ,
VP of Corp. Affairs and Sec.
|Mr. Jason Barker ,
Principal Accounting Officer and Sr. Director of Fin.
|Ms. Wing-Kei Tso CMA, CFM, CPA,
|Amounts are as of Dec 31, 2009 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|